Cochrane · systematic review · CD011461
Molecular‐targeted first‐line therapy for advanced gastric cancer
Song, H, Zhu, J, Lu, D · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings: Molecular‐targeted therapy plus chemotherapy compared to chemotherapy alone for people with advanced gastric cancer
Population: people with advanced gastric cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | HR 0.92 [0.8, 1.05] | 10 studies · 3843 participants | Low Downgraded: risk of bias, imprecision |
Progression‐free survival Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | HR 0.9 [0.78, 1.04] | 11 studies · 4014 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life (change from baseline in EORTC QOL30 global health status scale) Duration of Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | no estimate extracted | 1 study · 53 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Overall response rate Duration of Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | OR 1.24 [1, 1.55] | 11 studies · 3723 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse event (any) Duration of Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | OR 2.23 [1.27, 3.92] | 5 studies · 2290 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Severe adverse event (grade ≥ 3 ) Duration of Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone | OR 1.19 [1.03, 1.37] | 8 studies · 3800 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |